antifungal

brexafemme

Pharma

GSK amends deal with Scynexis amid Brexafemme manufacturing woes

GSK has downgraded a licensing deal for Scynexis' antifungal ibrexafungerp following an ongoing recall of the drug's approved form, Brexafemme.

Fraiser Kansteiner Jan 3, 2024 11:44am

GSK

GSK strikes antifungal deal as deadly pathogen raises alarm

Mar 30, 2023 11:16am

brexafemme

Scynexis to out license sole commercial med and cut sales team

Oct 20, 2022 3:45pm

brexafemme

Synexis' new data may broaden reach of game-changing Brexafemme

Apr 22, 2022 11:06am